Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $258.38 Analyst target: $138.37 Upside: -46.45%
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.